13.32
price down icon2.49%   -0.34
after-market Handel nachbörslich: 13.06 -0.26 -1.95%
loading

Novocure Ltd Aktie (NVCR) Neueste Nachrichten

pulisher
08:31 AM

NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st

08:31 AM
pulisher
Dec 09, 2025

Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - simplywall.st

Dec 09, 2025
pulisher
Dec 09, 2025

Marshall Wace LLP Sells 392,992 Shares of NovoCure Limited $NVCR - MarketBeat

Dec 09, 2025
pulisher
Dec 05, 2025

NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st

Dec 05, 2025
pulisher
Dec 04, 2025

Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance

Dec 04, 2025
pulisher
Dec 04, 2025

NovoCure (NASDAQ:NVCR) Stock Price Up 7%Time to Buy? - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

What is the fair value estimate for NovoCure Limited (038) stock in 2025Weekly Trade Report & Verified Stock Trade Ideas - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Is NovoCure’s 93% Five Year Share Price Slide Now Creating an Opportunity in 2025? - Yahoo Finance

Dec 04, 2025
pulisher
Dec 03, 2025

NovoCure Limited $NVCR Shares Purchased by American Century Companies Inc. - MarketBeat

Dec 03, 2025
pulisher
Dec 02, 2025

NovoCure stock rating reiterated at Buy by H.C. Wainwright amid CEO change - Investing.com Nigeria

Dec 02, 2025
pulisher
Dec 02, 2025

NovoCure (NASDAQ:NVCR) Shares Gap DownShould You Sell? - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Can NovoCure's Tumor Treating Fields Redefine Cancer Care By 2026? - RTTNews

Dec 02, 2025
pulisher
Dec 01, 2025

Novocure names Frank Leonard as new CEO, replacing Ashley Cordova By Investing.com - Investing.com Australia

Dec 01, 2025
pulisher
Dec 01, 2025

How Investors Are Reacting To NovoCure (NVCR) CEO Transition as Frank Leonard Takes the Helm - simplywall.st

Dec 01, 2025
pulisher
Dec 01, 2025

Novocure CEO Ashley Cordova resigns, Frank Leonard succeeds - TipRanks

Dec 01, 2025
pulisher
Dec 01, 2025

Novocure (NVCR) Appoints New CEO Amid Leadership Change - GuruFocus

Dec 01, 2025
pulisher
Dec 01, 2025

Novocure names Frank Leonard as new CEO, replacing Ashley Cordova - Investing.com India

Dec 01, 2025
pulisher
Dec 01, 2025

Novocure Ltd Announces CEO Transition - TradingView

Dec 01, 2025
pulisher
Dec 01, 2025

Novocure (NASDAQ: NVCR) elevates President Frank Leonard to CEO as Ashley Cordova resigns - Stock Titan

Dec 01, 2025
pulisher
Dec 01, 2025

Novocure Appoints Company President Frank Leonard as Chief Executive Officer - Yahoo Finance

Dec 01, 2025
pulisher
Nov 27, 2025

NovoCure (NASDAQ:NVCR) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat

Nov 27, 2025
pulisher
Nov 26, 2025

NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - MSN

Nov 26, 2025
pulisher
Nov 26, 2025

Novocure (NASDAQ: NVCR) to Present at 37th Piper Sandler Healthcare Conference on Dec. 2 - Stock Titan

Nov 26, 2025
pulisher
Nov 21, 2025

NovoCure Limited (NVCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 21, 2025
pulisher
Nov 19, 2025

Will NovoCure Limited stock attract more institutional investorsInsider Buying & Breakout Confirmation Trade Signals - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Novocure at Jefferies London: Expanding Horizons in Cancer Treatment By Investing.com - Investing.com South Africa

Nov 19, 2025
pulisher
Nov 19, 2025

Tangible book value per share of NovoCure Ltd. – DUS:038 - TradingView

Nov 19, 2025
pulisher
Nov 19, 2025

Published on: 2025-11-19 05:31:32 - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will NovoCure Limited stock benefit from green energy trendsPrice Action & AI Forecasted Entry/Exit Points - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Novocure at Jefferies London: Expanding Horizons in Cancer Treatment - Investing.com India

Nov 19, 2025
pulisher
Nov 17, 2025

NovoCure Limited (NVCR) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka

Nov 17, 2025
pulisher
Nov 17, 2025

Using flow based indicators on NovoCure LimitedTrade Performance Summary & Safe Entry Zone Identification - newser.com

Nov 17, 2025
pulisher
Nov 16, 2025

Why NovoCure Limited (038) stock could rally strongly2025 Analyst Calls & Weekly Watchlist of Top Performers - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

How interest rate cuts could boost NovoCure Limited stockWeekly Gains Summary & Verified Entry Point Signals - newser.com

Nov 16, 2025
pulisher
Nov 15, 2025

What sentiment indicators say about NovoCure Limited stockMarket Risk Report & Verified Short-Term Plans - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

Can NovoCure Limited stock deliver sustainable ROEEarnings Beat & Risk Managed Investment Entry Signals - newser.com

Nov 15, 2025
pulisher
Nov 15, 2025

NovoCure (NVCR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Nov 15, 2025
pulisher
Nov 14, 2025

Published on: 2025-11-14 04:19:47 - newser.com

Nov 14, 2025
pulisher
Nov 12, 2025

Should Rising Losses Despite Higher Sales Require Action From NovoCure (NVCR) Investors? - simplywall.st

Nov 12, 2025
pulisher
Nov 12, 2025

NVCR (NovoCure) ROA % : -11.44% (As of Sep. 2025) - GuruFocus

Nov 12, 2025
pulisher
Nov 12, 2025

2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon - Yahoo Finance

Nov 12, 2025
pulisher
Nov 12, 2025

Novocure (NASDAQ: NVCR) at Jefferies Healthcare, 2:00 p.m. GMT; webcast, 14-day replay - Stock Titan

Nov 12, 2025
pulisher
Nov 12, 2025

Novocure to Participate in 2025 Jefferies Global Healthcare Conference - Yahoo Finance

Nov 12, 2025
pulisher
Nov 11, 2025

NovoCure (NVCR): Assessing Valuation Following Q3 Sales Growth and Rising Net Losses - simplywall.st

Nov 11, 2025
$295.70
price up icon 0.52%
medical_devices STE
$251.79
price down icon 0.28%
medical_devices PHG
$26.62
price down icon 1.44%
$66.96
price down icon 2.87%
$83.96
price down icon 2.43%
medical_devices EW
$83.08
price down icon 1.38%
Kapitalisierung:     |  Volumen (24h):